Related Experiment Video
Updated: Jun 10, 2026
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre
R B Warren1, B C Brown, D Lavery
1Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester M6 8HD, U.K. richard.warren@manchester.ac.uk
Background:
There are few reports of the practical use of adalimumab outside of a clinical trial setting and, to our knowledge, none from the U.K.
Objectives:
We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K.
Methods:
A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. RESI;TS: Baseline Psoriasis Area and Severity Index (PASI) was 24+/-11 (range 9-54; n=46). After 4 months' treatment with adalimumab 64% (29/45), of patients had achieved PASI 75 (75% decrease from baseline) whilst 80% (36/45) of patients met NICE criteria for continuation of treatment. Therapy was well-tolerated. Importantly, 68% (21/31) of patients who had previously received another tumour necrosis factor alpha inhibitor met NICE criteria for continuation of treatment at 16 weeks.
Conclusions:
In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs.
